Gilgamesh starts subject dosing in major depressive disorder trial

Gilgamesh Pharmaceuticals has commenced subject dosing in a Phase IIa clinical trial of GM-1020 to treat major depressive disorder (MDD).

This clinical trial aims to evaluate the safety, tolerability, and efficacy of GM-1020 given as single and multiple oral doses.